These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27774524)

  • 21. IFN-γ mediates graft-versus-breast cancer effects via enhancing cytotoxic T lymphocyte activity.
    Zhao Q; Tong L; He N; Feng G; Leng L; Sun W; Xu Y; Wang Y; Xiang R; Li Z
    Exp Ther Med; 2014 Aug; 8(2):347-354. PubMed ID: 25009582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions.
    Mutis T; Aarts-Riemens T; Verdonck LF
    Haematologica; 2005 Oct; 90(10):1389-95. PubMed ID: 16219576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation.
    Robert S; Albring JC; Frebel K; Opitz C; Urh J; Wolf C; Heinrich C; Berdel WE; Stelljes M
    Bone Marrow Transplant; 2018 Jul; 53(7):807-819. PubMed ID: 29362503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma.
    Verneris MR; Ito M; Baker J; Arshi A; Negrin RS; Shizuru JA
    Biol Blood Marrow Transplant; 2001; 7(10):532-42. PubMed ID: 11760085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease.
    Hartmann N; Leithäuser F; Albers C; Duyster J; Möller P; Debatin KM; Strauss G
    Leukemia; 2011 May; 25(5):848-55. PubMed ID: 21331071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
    Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
    J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of bone marrow-derived mesenchymal stem cells in reduction of graft-versus-host disease by effecting CD4+CD25+ regulatory T cells in rats].
    Tian Y; Deng YB; Huang YJ; Na XD; Li Y; Ye MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1210-4. PubMed ID: 17204196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
    Maloney DG
    Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy].
    Tsukamoto H
    Yakugaku Zasshi; 2014; 134(10):1021-7. PubMed ID: 25274211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
    Ito M; Shizuru JA
    Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Level of Granzyme B-positive T-regulatory cells is a strong predictor biomarker of acute Graft-versus-host disease after day +30 after allo-HSCT.
    Drokov MY; Davydova JO; Kuzmina LA; Galtseva IV; Kapranov NM; Vasilyeva VA; Dubnyak DS; Koroleva OM; Mikhalcova ED; Popova NN; Parovichnikova EN; Savchenko VG
    Leuk Res; 2017 Mar; 54():25-29. PubMed ID: 28095351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reconstructing immunity after allogeneic transplantation.
    Giver CR; Li JM; Hossain MS; Lonial S; Waller EK
    Immunol Res; 2004; 29(1-3):269-82. PubMed ID: 15181288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Reconstitution kinetics of T helper cells subsets post unmanipulated allogeneic blood and marrow transplantation].
    Zhao XY; Zhao XS; Wang YZ; Chang YJ; Lv M; Wang HT; Han TT; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):745-50. PubMed ID: 24103870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
    Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
    J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
    Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
    Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hsp90 inhibition ameliorates CD4
    Berges C; Kerkau T; Werner S; Wolf N; Winter N; Hünig T; Einsele H; Topp MS; Beyersdorf N
    Immun Inflamm Dis; 2016 Dec; 4(4):463-473. PubMed ID: 27980780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
    Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
    Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human granzyme B regulatory B cells prevent effector CD4+CD25- T cell proliferation through a mechanism dependent from lymphotoxin alpha.
    Sailliet N; Mai HL; Dupuy A; Tilly G; Fourgeux C; Braud M; Giral M; Robert JM; Degauque N; Danger R; Poschmann J; Brouard S
    Front Immunol; 2023; 14():1183714. PubMed ID: 37588598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.